Login to Your Account



Clinic Roundup


Tuesday, December 27, 2011
• Protox Therapeutics Inc., of San Diego, completed dosing of the second cohort in its transrectal study of PRX302 for the treatment of benign prostatic hyperplasia. PRX302 is a genetically engineered version of the pore forming protein proaerolysin designed to disrupt membrane integrity in prostate cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription